Premium
Anti‐tumour immunotherapy with V γ9 V δ2 T lymphocytes: from the bench to the bedside
Author(s) -
Braza Mounia S.,
Klein Bernard
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12090
Subject(s) - immunotherapy , cancer immunotherapy , immunology , medicine , lymphocyte , immune system , cancer research , biology
Summary Gamma delta (γδ) Τ cells are non‐conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti‐tumour activity against many cancers and suggest that γδ Τ cell‐mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.